Gossamer Bio (GOSS) Operating Expenses (2018 - 2026)

Gossamer Bio has reported Operating Expenses for 9 years, with the latest figure at $35.3 million in Q2 2026.

• On a quarterly basis, Operating Expenses fell 29.73% year-over-year to $35.3 million in Q2 2026; TTM through Jun 2026 was $219.4 million, a 18.04% increase from a year earlier, with the FY2025 full-year figure at $219.2 million, up 25.53% from the prior year.
• Operating Expenses was $35.3 million for Q2 2026 at Gossamer Bio, down from $61.8 million in the prior quarter.
• The five-year high for Operating Expenses was $62.4 million in Q3 2025, with the low at $35.3 million in Q2 2026.
• Average Operating Expenses over 5 years is $49.6 million, with a median of $48.5 million recorded in 2023.
• The sharpest annual moves came in 2025 and 2026: Operating Expenses surged 43.8% in 2025, then retreated 29.73% in 2026.
• Over 5 years, Operating Expenses stood at $54.4 million in 2022, then retreated by 9.81% to $49.0 million in 2023, then fell by 7.18% to $45.5 million in 2024, then soared by 31.49% to $59.8 million in 2025, then tumbled by 40.99% to $35.3 million in 2026.
• The last three Operating Expenses figures came in at $35.3 million (Q2 2026), $61.8 million (Q1 2026), and $59.8 million (Q4 2025), per Business Quant data.